FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Traynor

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Radioligand Assay

Physiology

Binding, Competitive

Concepts & Ideas

Co-author Network

Publications

TOP 3
Benjamin M Greedy; Konstantinos Grivas; John W Lewis; Mark P Thomas; John R Traynor; Mario D Aceto; Ashley Archambeau; Kelly Bosse; Faye Bradbury; Gerta Cami-Kobeci; Mary J Clark; Stephen M Husbands
Orvinols with mixed kappa/mu opioid receptor agonist activity.
Henry I Mosberg; Katarzyna Sobczyk-Kojiro; Larisa Yeomans; Jessica P Anand; Aaron M Bender; Mary J Clark; Aubrie A Harland; Emily Jutkiewicz; John R Traynor
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Joseph J Casal-Dominguez; Mary Clark; Stephen M Husbands; John R Traynor; Sarah J Bailey
In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Traynor (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Benjamin M Greedy; Konstantinos Grivas; John W Lewis; Mark P Thomas; John R Traynor; Mario D Aceto; Ashley Archambeau; Kelly Bosse; Faye Bradbury; Gerta Cami-Kobeci; Mary J Clark; Stephen M Husbands
Orvinols with mixed kappa/mu opioid receptor agonist activity.
Journal of medicinal chemistry 2013;56(8):3207-16.
2013: Henry I Mosberg; Katarzyna Sobczyk-Kojiro; Larisa Yeomans; Jessica P Anand; Aaron M Bender; Mary J Clark; Aubrie A Harland; Emily Jutkiewicz; John R Traynor
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Journal of medicinal chemistry 2013;56(5):2139-49.
2013: Joseph J Casal-Dominguez; Mary Clark; Stephen M Husbands; John R Traynor; Sarah J Bailey
In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor.
Journal of psychopharmacology (Oxford, England) 2013;27(2):192-202.
2012: Humphrey A Moynihan; Lauren C S Purington; Mark P Thomas; John R Traynor; James H Woods; Mario D Aceto; Jillian Broadbear; Ian Derrick; Benjamin M Greedy; Louis S Harris; Stephen M Husbands; John W Lewis
Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
Journal of medicinal chemistry 2012;55(22):9868-74.
2012: Jessica P Anand; Irina D Pogozheva; Lauren C Purington; John R Traynor; Henry I Mosberg
Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
Chemical biology & drug design 2012;80(5):763-70.
2012: John R Traynor
μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology.
Drug and alcohol dependence 2012;121(3):173-80.
2011: Lauren C Purington; Irina D Pogozheva; Katarzyna Sobczyk-Kojiro; John R Traynor; Henry I Mosberg
Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
ACS chemical biology 2011;6(12):1375-81.
2011: Elizabeth Peckham; Jill B Becker; Steven M Graves; Emily Jutkiewicz; John R Traynor
Role of gonadal hormones on mu-opioid-stimulated [³⁵S]GTPγS binding and morphine-mediated antinociception in male and female Sprague-Dawley rats.
Psychopharmacology 2011;218(3):483-92.
2011: David L Roman; John R Traynor
Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction.
Journal of medicinal chemistry 2011;54(21):7433-40.
2011: Jennifer T Lamberts; richard mortensen; Emily Jutkiewicz; John R Traynor
μ-Opioid receptor coupling to Gα(o) plays an important role in opioid antinociception.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2011;36(10):2041-53.
2011: Qin Wang; John R Traynor
Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk.
The Journal of biological chemistry 2011;286(10):7854-64.
2011: Erica S Levitt; Lauren C Purington; John R Traynor
Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.
Molecular pharmacology 2011;79(3):461-71.
2010: Rama Pichika; Douglas M Jewett; Philip S Sherman; John R Traynor; Stephen M Husbands; James H Woods; Michael R Kilbourn
Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists.
Nuclear medicine and biology 2010;37(8):989-96.
2010: Jeffery N Talbot; Emily Jutkiewicz; Steven M Graves; Crystal F Clemans; Melanie R Nicol; richard mortensen; Xinyan Huang; Richard Neubig; John R Traynor
RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(24):11086-91.
2010: John R Traynor
Regulator of G protein-signaling proteins and addictive drugs.
Annals of the New York Academy of Sciences 2010;1187():341-52.
2010: Jeffery N Talbot; David Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard Neubig; John R Traynor
Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.
Journal of neurochemistry 2010;112(4):1026-34.
2010: Mark Connor; John R Traynor
Constitutively active μ-opioid receptors.
Methods in enzymology 2010;484():445-69.
2009: Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
Journal of medicinal chemistry 2009;52(23):7724-31.
2009: Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.
Journal of medicinal chemistry 2009;52(21):6926-30.
2009: Susan L Ingram; John R Traynor
Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential.
British journal of pharmacology 2009;158(1):154-6.
2009: Erica S Levitt; Mary J Clark; Paul M Jenkins; Jeffrey R Martens; John R Traynor
Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase.
The Journal of biological chemistry 2009;284(33):22108-22.
2009: Qin Wang; Lee-Yuan Liu-Chen; John R Traynor
Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells.
The Journal of biological chemistry 2009;284(27):18357-67.
2009: Faye Bradbury; Jennifer C Zelnik; John R Traynor
G protein independent phosphorylation and internalization of the delta-opioid receptor.
Journal of neurochemistry 2009;109(5):1526-35.
2009: M F Divin; Faye Bradbury; F I Carroll; John R Traynor
Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
British journal of pharmacology 2009;156(7):1044-53.
2009: H Moynihan; Andrew R Jales; B M Greedy; David Rennison; Jillian H Broadbear; L Purington; John R Traynor; James H Woods; John W Lewis; Stephen M Husbands
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.
Journal of medicinal chemistry 2009;52(6):1553-7.
2009: Gerta Cami-Kobeci; Adrian P Neal; Faye Bradbury; Lauren C Purington; Mario D Aceto; Louis S Harris; John W Lewis; John R Traynor; Stephen M Husbands
Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
Journal of medicinal chemistry 2009;52(6):1546-52.
2009: John R Traynor; Dimitra Terzi; Barbara J Caldarone; Venetia Zachariou
RGS9-2: probing an intracellular modulator of behavior as a drug target.
Trends in pharmacological sciences 2009;30(3):105-11.
2008: Christopher J Brinkerhoff; John R Traynor; Jennifer J Linderman
Collision coupling, crosstalk, and compartmentalization in G-protein coupled receptor systems: can a single model explain disparate results?
Journal of theoretical biology 2008;255(3):278-86.
2008: Kelly E Bosse; Emily Jutkiewicz; Margaret E Gnegy; John R Traynor
The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.
Neuropharmacology 2008;55(5):755-62.
2008: Hong Xie; James H Woods; John R Traynor; Mei-Chuan Ko
The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
Anesthesia and analgesia 2008;106(6):1873-81.
2008: Susan L Mercer; Jamaluddin Shaikh; John R Traynor; Rae Reiko Matsumoto; Andrew Coop
Nitrile analogs of meperidine as high affinity and selective sigma-1 receptor ligands.
European journal of medicinal chemistry 2008;43(6):1304-8.
2008: Mary J Clark; Jennifer J Linderman; John R Traynor
Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model.
Molecular pharmacology 2008;73(5):1538-48.
2008: Christopher W Cunningham; Susan L Mercer; Hazem E Hassan; John R Traynor; Natalie D. Eddington; Andrew Coop
Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs.
Journal of medicinal chemistry 2008;51(7):2316-20.
2008: Mary F Divin; Mei-Chuan Ko; John R Traynor
Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.
European journal of pharmacology 2008;583(1):48-55.
2008: William E Fantegrossi; J R Ciullo; K T Wakabayashi; Richard De La Garza; John R Traynor; James H Woods
A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse.
Neuroscience 2008;151(2):533-43.
2008: Matthew D Metcalf; Mario D Aceto; Louis S Harris; James H Woods; John R Traynor; Andrew Coop; Everette L May
The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.
Bioorganic & medicinal chemistry 2008;16(2):869-73.
2007: Yiqiang Li; Stephen M Husbands; Mary F Mahon; John R Traynor; Michael G Rowan
Isolation and chemical modification of clerodane diterpenoids from Salvia species as potential agonists at the kappa-opioid receptor.
Chemistry & biodiversity 2007;4(7):1586-93.
2007: Jun-Xu Li; Ginger L Becker; John R Traynor; Ze-Hui Gong; Charles France
Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics 2007;321(1):227-36.
2007: David Roman; Jeffery N Talbot; Rebecca A Roof; Roger K Sunahara; John R Traynor; Richard Neubig
Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay.
Molecular pharmacology 2007;71(1):169-75.
2006: Mary J Clark; John R Traynor
Mediation of adenylyl cyclase sensitization by PTX-insensitive GalphaoA, Galphai1, Galphai2 or Galphai3.
Journal of neurochemistry 2006;99(6):1494-504.
2006: David Rennison; Humphrey A Moynihan; John R Traynor; John W Lewis; Stephen M Husbands
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.
Journal of medicinal chemistry 2006;49(20):6104-10.
2006: Nick P R Nieland; Humphrey A Moynihan; Simon Carrington; Jillian H Broadbear; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
Journal of medicinal chemistry 2006;49(17):5333-8.
2006: Mary J Clark; Cheryse A Furman; Timra D Gilson; John R Traynor
Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.
The Journal of pharmacology and experimental therapeutics 2006;317(2):858-64.
2006: Elizabeth Peckham; John R Traynor
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
The Journal of pharmacology and experimental therapeutics 2006;316(3):1195-201.
2006: Patrick A Lester; John R Traynor
Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Brain research 2006;1073-1074():290-6.
2006: Christoph Czermak; Michael Lehofer; Peter M Liebmann; John R Traynor
[35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2, hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and norepinephrine.
European journal of pharmacology 2006;531(1-3):20-4.
2006: Mei-Chuan Ko; Mary F Divin; Heeseung Lee; James H Woods; John R Traynor
Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.
The Journal of pharmacology and experimental therapeutics 2006;316(2):772-9.
2006: Verónica González-Núñez; Alejandro Barrallo; John R Traynor; Raquel E Rodríguez
Characterization of opioid-binding sites in zebrafish brain.
The Journal of pharmacology and experimental therapeutics 2006;316(2):900-4.
2005: Magdalena J Przydzial; Irina D Pogozheva; JC Ho; K E Bosse; E Sawyer; John R Traynor; Henry I Mosberg
Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
The journal of peptide research : official journal of the American Peptide Society 2005;66(5):255-62.
2005: Emily Jutkiewicz; Kenner C Rice; John R Traynor; James H Woods
Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats.
Psychopharmacology 2005;182(4):588-96.
2005: Elizabeth Peckham; Laura M Barkley; Mary F Divin; Theodore J Cicero; John R Traynor
Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
Brain research 2005;1058(1-2):137-47.
2005: Emily Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods
Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.
The Journal of pharmacology and experimental therapeutics 2005;315(1):414-22.
2005: Cédric Chauvignac; Carl N Miller; Sanjay K Srivastava; John W Lewis; Stephen M Husbands; John R Traynor
Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.
Journal of medicinal chemistry 2005;48(5):1676-9.
2005: Magdalena J Przydzial; Irina D Pogozheva; K E Bosse; S M Andrews; T A Tharp; John R Traynor; Henry I Mosberg
Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
The journal of peptide research : official journal of the American Peptide Society 2005;65(3):333-42.
2005: Emily Jutkiewicz; Nicholas P Walker; John E Folk; Kenner C Rice; Philip S Portoghese; James H Woods; John R Traynor
Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1314-20.
2005: Stephen M Husbands; Claire L Neilan; Jillian H Broadbear; Peter Grundt; Simon Breeden; Mario D Aceto; James H Woods; John W Lewis; John R Traynor
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
European journal of pharmacology 2005;509(2-3):117-25.
2005: John R Traynor; Richard Neubig
Regulators of G protein signaling & drugs of abuse.
Molecular interventions 2005;5(1):30-41.
2005: Mary J Clark; John R Traynor
Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
The Journal of pharmacology and experimental therapeutics 2005;312(2):809-15.
2004: Sanjay K Srivastava; Shefali Shefali; Carl N Miller; Mario D Aceto; John R Traynor; John W Lewis; Stephen M Husbands
Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
Journal of medicinal chemistry 2004;47(26):6645-8.
2004: Claire L Neilan; Stephen M Husbands; Simon Breeden; Mei-Chuan Ko; Mario D Aceto; John W Lewis; James H Woods; John R Traynor
Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
European journal of pharmacology 2004;499(1-2):107-16.
2004: Mary J Clark; Richard Neubig; John R Traynor
Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.
The Journal of pharmacology and experimental therapeutics 2004;310(1):215-22.
2004: Anna Waller; Karyn L Sutton; Tamara L Kinzer-Ursem; Afaf Absood; John R Traynor; Jennifer J Linderman; Geneva M Omann
Receptor binding kinetics and cellular responses of six N-formyl peptide agonists in human neutrophils.
Biochemistry 2004;43(25):8204-16.
2004: Matthew A Romano; Robert McNish; Elisabeth M Seymour; John R Traynor; Steven F Bolling
Differential effects of opioid peptides on myocardial ischemic tolerance.
The Journal of surgical research 2004;119(1):46-50.
2004: Emily Jutkiewicz; Erik B Eller; John E Folk; Kenner C Rice; John R Traynor; James H Woods
Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats.
The Journal of pharmacology and experimental therapeutics 2004;309(1):173-81.
2004: Mary J Clark; John R Traynor
Assays for G-protein-coupled receptor signaling using RGS-insensitive Galpha subunits.
Methods in enzymology 2004;389():155-69.
2003: Charlotte Harrison; John R Traynor
The [35S]GTPgammaS binding assay: approaches and applications in pharmacology.
Life sciences 2003;74(4):489-508.
2003: Shannon L Black; Cédric Chauvignac; Peter Grundt; Carl N Miller; Susan Wood; John R Traynor; John W Lewis; Stephen M Husbands
Guanidino N-substituted and N,N-disubstituted derivatives of the kappa-opioid antagonist GNTI.
Journal of medicinal chemistry 2003;46(25):5505-11.
2003: Elisabeth M Seymour; Shu-Yung James Wu; Melissa A Kovach; Matthew A Romano; John R Traynor; William C Claycomb; Steven F Bolling
HL-1 myocytes exhibit PKC and K(ATP) channel-dependent delta opioid preconditioning.
The Journal of surgical research 2003;114(2):187-94.
2003: Deborah L Heyl; Stephen E Schullery; Kutralanathan Renganathan; Malika N Jayamaha; David W Rodgers; John R Traynor
pKa and volume of residue one influence delta/mu opioid binding: QSAR analysis of tyrosine replacement in a nonselective deltorphin analogue.
Bioorganic & medicinal chemistry 2003;11(17):3761-8.
2003: Mei-Chuan Ko; Heeseung Lee; Charlotte Harrison; Mary J Clark; H F Song; Norah N Naughton; James H Woods; John R Traynor
Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
The Journal of pharmacology and experimental therapeutics 2003;306(1):179-86.
2003: Elisabeth Greiner; Mariana Spetea; Roland Krassnig; Falko Schüllner; Mario D Aceto; Louis S Harris; John R Traynor; James H Woods; Andrew Coop; Helmut Schmidhammer
Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
Journal of medicinal chemistry 2003;46(9):1758-63.
2003: Peter Grundt; Andrew R Jales; John R Traynor; John W Lewis; Stephen M Husbands
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
Journal of medicinal chemistry 2003;46(8):1563-6.
2003: Mary J Clark; Charlotte Harrison; Huailing Zhong; Richard Neubig; John R Traynor
Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
The Journal of biological chemistry 2003;278(11):9418-25.
2003: Huailing Zhong; Susan M Wade; Peter J Woolf; Jennifer J Linderman; John R Traynor; Richard Neubig
A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding.
The Journal of biological chemistry 2003;278(9):7278-84.
2003: Everette L May; Andrew Coop; James H Woods; Mario D Aceto; Edward R Bowman; Louis S Harris; John R Traynor
N-(trifluoromethyl)benzyl substituted N-normetazocines and N-norketobemidones.
Bioorganic & medicinal chemistry 2003;11(1):31-3.
2002: Daniel C Broom; Joshua F Nitsche; John E Pintar; Kenner C Rice; James H Woods; John R Traynor
Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice.
The Journal of pharmacology and experimental therapeutics 2002;303(2):723-9.
2002: Daniel C Broom; Emily Jutkiewicz; John E Folk; John R Traynor; Kenner C Rice; James H Woods
Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats.
Psychopharmacology 2002;164(1):42-8.
2002: Daniel C Broom; Emily Jutkiewicz; Kenner C Rice; John R Traynor; James H Woods
Behavioral effects of delta-opioid receptor agonists: potential antidepressants?
Japanese journal of pharmacology 2002;90(1):1-6.
2002: Daniel C Broom; Emily Jutkiewicz; John E Folk; John R Traynor; Kenner C Rice; James H Woods
Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(6):744-55.
2002: Mei-Chuan Ko; Norah N Naughton; John R Traynor; Michael S Song; James H Woods; Kenner C Rice; A T McKnight
Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors.
British journal of pharmacology 2002;135(4):943-50.
2002: Sanjay K Srivastava; Stephen M Husbands; Mario D Aceto; Carl N Miller; John R Traynor; John W Lewis
4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity.
Journal of medicinal chemistry 2002;45(2):537-40.
2002: A Alt; Mary J Clark; James H Woods; John R Traynor
Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.
British journal of pharmacology 2002;135(1):217-25.
2002: John R Traynor; Mary J Clark; Ann E Remmers
Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists.
The Journal of pharmacology and experimental therapeutics 2002;300(1):157-61.
2001: Eduardo R Butelman; Mei-Chuan Ko; John R Traynor; JA Vivian; Mary Jeanne Kreek; James H Woods
GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics 2001;298(3):1049-59.
2001: A Alt; IJ McFadyen; C D Fan; James H Woods; John R Traynor
Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
The Journal of pharmacology and experimental therapeutics 2001;298(1):116-21.
2000: Everette L May; Arthur E Jacobson; M V Mattson; John R Traynor; James H Woods; Louis S Harris; Edward R Bowman; Mario D Aceto
Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.
Journal of medicinal chemistry 2000;43(26):5030-6.
2000: Claire L Neilan; E Kenyon; M A Kovach; K Bowden; W C Claycomb; John R Traynor; Steven F Bolling
An immortalized myocyte cell line, HL-1, expresses a functional delta -opioid receptor.
Journal of molecular and cellular cardiology 2000;32(12):2187-93.
2000: IJ McFadyen; Katarzyna Sobczyk-Kojiro; M J Schaefer; JC Ho; John R Omnaas; Henry I Mosberg; John R Traynor
Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.
The Journal of pharmacology and experimental therapeutics 2000;295(3):960-6.
2000: Andrew Coop; Arthur E Jacobson; Mario D Aceto; Louis S Harris; John R Traynor; James H Woods; Kenner C Rice
N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole.
Bioorganic & medicinal chemistry letters 2000;10(21):2449-51.
2000: IJ McFadyen; Hani Houshyar; L Y Liu-Chen; James H Woods; John R Traynor
The steroid 17alpha-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3, 5-dien-20-one (SC17599) is a selective mu-opioid agonist: implications for the mu-opioid pharmacophore.
Molecular pharmacology 2000;58(4):669-76.
2000: Daniel C Broom; L Guo; Andrew Coop; Stephen M Husbands; John W Lewis; James H Woods; John R Traynor
BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1195-200.
2000: Jillian H Broadbear; Tina L Sumpter; T F Burke; Stephen M Husbands; John W Lewis; James H Woods; John R Traynor
Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
The Journal of pharmacology and experimental therapeutics 2000;294(3):933-40.
2000: I Derrick; Claire L Neilan; J Andes; Stephen M Husbands; James H Woods; John R Traynor; John W Lewis
3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
Journal of medicinal chemistry 2000;43(17):3348-50.
2000: Raquel E Rodriguez; Alejandro Barrallo; F Garcia-Malvar; IJ McFadyen; Rogelio Gonzalez-Sarmiento; John R Traynor
Characterization of ZFOR1, a putative delta-opioid receptor from the teleost zebrafish (Danio rerio).
Neuroscience letters 2000;288(3):207-10.
2000: Ann E Remmers; Mary J Clark; A Alt; F Medzihradsky; James H Woods; John R Traynor
Activation of G protein by opioid receptors: role of receptor number and G-protein concentration.
European journal of pharmacology 2000;396(2-3):67-75.
2000: Hani Houshyar; I J Mc Fadyen; James H Woods; John R Traynor
Antinociceptive and other behavioral effects of the steroid SC17599 are mediated by the mu-opioid receptor.
European journal of pharmacology 2000;395(2):121-8.
2000: IJ McFadyen; JC Ho; Henry I Mosberg; John R Traynor
Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation.
The journal of peptide research : official journal of the American Peptide Society 2000;55(3):255-61.
1999: John R Traynor; L Guo; Andrew Coop; J W Lewis; James H Woods
Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
The Journal of pharmacology and experimental therapeutics 1999;291(3):1093-9.
1999: Arpád Márki; Krisztina Monory; Ferenc Otvös; G Tóth; Roland Krassnig; Helmut Schmidhammer; John R Traynor; B P Roques; R Maldonado; Anna Borsodi
Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
European journal of pharmacology 1999;383(2):209-14.
1999: Claire L Neilan; Huda Akil; James H Woods; John R Traynor
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.
British journal of pharmacology 1999;128(3):556-62.
1999: M D Johnson; M C H Ko; Mei-Chuan Ko; John R Traynor; Henry I Mosberg; Norah N Naughton; James H Woods
The effects of the phyllolitorin analogue [desTrp(3), Leu(8)]phyllolitorin on scratching induced by bombesin and related peptides in rats.
Brain research 1999;839(1):194-8.
1999: K O Lee; Huda Akil; James H Woods; John R Traynor
Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.
European journal of pharmacology 1999;378(3):323-30.
1999: JA Vivian; M B DeYoung; Tina L Sumpter; John R Traynor; John W Lewis; James H Woods
kappa-Opioid receptor effects of butorphanol in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics 1999;290(1):259-65.
1998: Alejandro Barrallo; F G Malvar; R Gonzalez; Raquel E Rodriguez; John R Traynor
Cloning and characterization of a delta opioid receptor from zebrafish.
Biochemical Society transactions 1998;26(4):S360.
1998: C Wang; IJ McFadyen; John R Traynor; Henry I Mosberg
Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models.
Bioorganic & medicinal chemistry letters 1998;8(19):2685-8.
1998: Stephen M Husbands; J Sadd; Jillian H Broadbear; James H Woods; J Martin; John R Traynor; Mario D Aceto; Edward R Bowman; Louis S Harris; John W Lewis
3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Journal of medicinal chemistry 1998;41(18):3493-8.
1998: John R Traynor
Epibatidine and pain.
British journal of anaesthesia 1998;81(1):69-76.
1998: A Alt; A Mansour; Huda Akil; F Medzihradsky; John R Traynor; James H Woods
Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor.
The Journal of pharmacology and experimental therapeutics 1998;286(1):282-8.
1998: Mei-Chuan Ko; Eduardo R Butelman; John R Traynor; James H Woods
Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics 1998;285(2):518-26.
1998: James H Woods; F Medzihradsky; Charles B Smith; Gail Winger; John R Traynor
Evaluation of new compounds for opioid activity (1997).
NIDA research monograph 1998;178():408-28.
1998: K M Bell; John R Traynor
Dynorphin A(1-8): stability and implications for in vitro opioid activity.
Canadian journal of physiology and pharmacology 1998;76(3):325-33.
1997: P G Szekeres; John R Traynor
Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
The Journal of pharmacology and experimental therapeutics 1997;283(3):1276-84.
1997: J Elliott; L Guo; John R Traynor
Tolerance to mu-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5'-O-(3-[35S]-thio)triphosphate binding.
British journal of pharmacology 1997;121(7):1422-8.
1995: Helmut Schmidhammer; H K Jennewein; Roland Krassnig; John R Traynor; D Patel; K Bell; G Froschauer; K Mattersberger; C Jachs-Ewinger; P Jura
Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime.
Journal of medicinal chemistry 1995;38(16):3071-7.
1995: John R Traynor; Stefan R Nahorski
Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Molecular pharmacology 1995;47(4):848-54.
1995: J Elliott; John R Traynor
Evidence for lack of modulation of mu-opioid agonist action by delta-opioid agonists in the mouse vas deferens and guinea-pig ileum.
British journal of pharmacology 1995;114(5):1064-8.
1994: Nadia M J Rupniak; Smita Patel; Rose Marwood; J Webb; John R Traynor; J Elliott; S B Freedman; S R Fletcher; Raymond G Hill
Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity.
British journal of pharmacology 1994;113(4):1487-93.
1994: Robert A Wilcox; R A John Challiss; John R Traynor; Abdul Fauq; V I Ognayanov; Alan P Kozikowski; Stefan R Nahorski
Molecular recognition at the myo-inositol 1,4,5-trisphosphate receptor. 3-position substituted myo-inositol 1,4,5-trisphosphate analogues reveal the binding and Ca2+ release requirements for high affinity interaction with the myo-inositol 1,4,5-trisphosphate receptor.
The Journal of biological chemistry 1994;269(43):26815-21.
1994: J Elliott; D Smart; D G Lambert; John R Traynor
Characterisation of mu-opioid receptors on SH-SY5Y cells using naloxonazine and beta-funaltrexamine.
European journal of pharmacology 1994;268(3):447-50.
1994: John R Traynor
Opioid receptors and their subtypes: focus on peripheral isolated tissue preparations.
Neurochemistry international 1994;24(5):427-32.
1993: J Elliott; D Smart; John R Traynor; D G Lambert
Characterization of the mu-opioid receptors on SH-SY5Y cells using beta-funaltrexamine (beta-FNA) and naloxonazine.
Biochemical Society transactions 1993;21(4):469S.
1993: D M Dixon; John R Traynor
Conversion of dynorphin A(1-8) to [Leu5]-enkephalin in rat central nervous tissue during development.
Neuropeptides 1993;25(2):121-5.
1993: John R Traynor; J Elliott
delta-Opioid receptor subtypes and cross-talk with mu-receptors.
Trends in pharmacological sciences 1993;14(3):84-6.
1992: F D Rodriguez; E Bardaji; John R Traynor
Differential effects of Mg2+ and other divalent cations on the binding of tritiated opioid ligands.
Journal of neurochemistry 1992;59(2):467-72.
1991: T G Franklin; John R Traynor
Alkylation with beta-funaltrexamine suggests differences between mu-opioid receptor systems in guinea-pig brain and myenteric-plexus.
British journal of pharmacology 1991;102(3):718-22.
1990: D M Dixon; John R Traynor
Evidence that the agonist action of dynorphin A(1-8) in the guinea-pig myenteric-plexus may be mediated partly through conversion to [Leu5]enkephalin.
British journal of pharmacology 1990;101(3):674-8.
1990: John R Traynor; J C Hunter; Raquel E Rodriguez; R G Hill; J Hughes
Delta-opioid receptor binding sites in rodent spinal cord.
British journal of pharmacology 1990;100(2):319-23.
1990: H Rogers; A G Hayes; P J Birch; John R Traynor; A J Lawrence
The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors.
The Journal of pharmacy and pharmacology 1990;42(5):358-9.
1990: D M Dixon; John R Traynor
Formation of [Leu5]enkephalin from dynorphin A(1-8) by rat central nervous tissue in vitro.
Journal of neurochemistry 1990;54(4):1379-85.
1990: A J Lawrence; John R Traynor
Characterisation of opioid binding sites using selective antagonists.
Progress in clinical and biological research 1990;328():121-4.
1989: M S Wood; F D Rodriguez; John R Traynor
Characterisation of kappa-opioid binding sites in rat and guinea-pig spinal cord.
Neuropharmacology 1989;28(10):1041-6.
1989: J C Gill; S E Khan; P M Lockey; B A Marples; John R Traynor
Estrogen receptor binding and alkylating properties of A-ring aromatic 17,20- and 20,21-epoxy-norpregnanediols: potential target selective antitumour agents.
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):1123-4.
1989: M S Wood; John R Traynor
[3H]diprenorphine binding to kappa-sites in guinea-pig and rat brain: evidence for apparent heterogeneity.
Journal of neurochemistry 1989;53(1):173-8.
1989: John R Traynor
Subtypes of the kappa-opioid receptor: fact or fiction?
Trends in pharmacological sciences 1989;10(2):52-3.
1987: John R Traynor; M S Wood
Distribution of opioid binding sites in spinal cord.
Neuropeptides 1987;10(4):313-20.
1987: H W Kosterlitz; Stewart J Paterson; L E Robson; John R Traynor
Effects of cations on binding, in membrane suspensions, of various opioids at mu-sites of rabbit cerebellum and kappa-sites of guinea-pig cerebellum.
British journal of pharmacology 1987;91(2):431-7.
1987: John R Traynor; Alistair D Corbett; H W Kosterlitz
Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
European journal of pharmacology 1987;137(1):85-9.
1986: J F Stocker; John R Traynor
The action of various venoms on Escherichia coli.
The Journal of applied bacteriology 1986;61(5):383-8.
1986: J C Gill; P M Lockey; B A Marples; John R Traynor
3,17 beta-Dihydroxy-20,21-epoxy-19-norpregna-1,3,5(10)-trienes: synthesis, rearrangement, cytotoxicity, and estrogen-receptor binding.
Journal of medicinal chemistry 1986;29(8):1537-40.
1986: N Appelmans; J A Carroll; M J Rance; E J Simon; John R Traynor
Sodium ions increase the binding of the antagonist peptide ICI 174864 to the delta-opiate receptor.
Neuropeptides 1986;7(2):139-43.
1986: John R Traynor; M S Wood; J A Carroll; M J Rance
Kappa opioid binding sites in rat spinal cord.
NIDA research monograph 1986;75():73-6.
1985: L Miller; M J Rance; J S Shaw; John R Traynor
Conversion of dynorphin-(1-9) to [Leu5]enkephalin by the mouse vas deferens in vitro.
European journal of pharmacology 1985;116(1-2):159-63.
1985: R Cotton; H W Kosterlitz; Stewart J Paterson; M J Rance; John R Traynor
The use of [3H]-[D-Pen2,D-Pen5]enkephalin as a highly selective ligand for the delta-binding site.
British journal of pharmacology 1985;84(4):927-32.
1984: John R Traynor; M J Rance
Opiate binding in the rat spinal cord: evidence for mu and delta sites.
Neuropeptides 1984;5(1-3):81-4.
1984: L S Chagonda; P M Lockey; B A Marples; John R Traynor
Synthesis and cytotoxic activity of estrogen alpha-methylene-delta-lactones.
Steroids 1984;43(3):283-92.
1982: K S Authi; John R Traynor
Stimulation of polymorphonuclear leucocyte phospholipase A2 activity by chloroquine and mepacrine.
The Journal of pharmacy and pharmacology 1982;34(11):736-8.
1982: John R Traynor; P D Kelly; M J Rance
Multiple opiate binding sites in rat spinal cord.
Life sciences 1982;31(12-13):1377-80.
1982: K S Authi; A Solanky; John R Traynor
Inhibition of an inflammatory exudate phospholipase A2 by an endogenous inhibitor of polymorphonuclear leucocytes.
Pharmacological research communications 1982;14(5):401-7.
1982: John R Traynor; P D Kelly
Effects of narcotic analgesics on lipase activity in vitro.
Pharmacological research communications 1982;14(4):327-39.
1981: John R Traynor; K S Authi
Phospholipase A2 activity of lysosomal origin secreted by polymorphonuclear leucocytes during phagocytosis or on treatment with calcium.
Biochimica et biophysica acta 1981;665(3):571-7.
1980: J A Horne; J E Percival; John R Traynor
Aspirin and human sleep.
Electroencephalography and clinical neurophysiology 1980;49(3-4):409-13.
1980: S S Dehal; B A Marples; R J Stretton; John R Traynor
Steroidal alpha-methylene delta-lactones as potential antitumor agents.
Journal of medicinal chemistry 1980;23(1):90-2.
1980: K S Authi; John R Traynor
Release of lysosomal phospholipase A from rabbit neutrophil leucocytes [proceedings].
British journal of pharmacology 1980;68(1):125P.
1979: K S Authi; John R Traynor
Effects of antimalarial drugs on phospholipase A2 [proceedings].
British journal of pharmacology 1979;66(3):496P.
1979: W G Salt; John R Traynor
Interactions between amethocaine (tetracaine) and non-growing cultures of Escherichia coli.
The Journal of pharmacy and pharmacology 1979;31(1):41-2.
1976: H Kunze; N Nahas; John R Traynor; M Wurl
Effects of local anaesthetics on phospholipases.
Biochimica et biophysica acta 1976;441(1):93-102.
1976: John R Traynor; H Kunze
Effects of local anaesthetics on the lipase of Rhizopus arrhizus.
Biochimica et biophysica acta 1976;424(2):246-52.
1975: John R Traynor; H Kunze
Inhibition of rat liver cholesterol esterase by local anaesthetics.
Biochimica et biophysica acta 1975;409(1):68-74.